RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway

Published:2024-08-28 Issue: Volume: Page:
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Xing Shigui¹,Li Dongbing²,Zhao Qi³

Affiliation:

1. Department of Thoracic Surgery, Nanjing Gaochun People’s Hospital, Nanjing 211300, Jiangsu, China

2. Scientific Research Center, Beijing ChosenMed Clinical Laboratory Co., Ltd., Beijing 100176, China

3. Department of Pulmonary and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu, China

Publisher

Impact Journals, LLC

Reference53 articles.

1. Cancer statistics, 2023.;Jemal;CA Cancer J Clin,2023

2. Non-small cell lung cancer in China.;Zhou;Cancer Commun (Lond),2022

3. Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer.;Gibbons;Cold Spring Harb Perspect Med,2022

4. Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy.;Jois;Curr Med Chem,2020

5. Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint.;Volarević;Oncogene,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP